Last updated: May 4, 2023
Sponsor: Regina Elena Cancer Institute
Overall Status: Active - Recruiting
Phase
N/A
Condition
Multiple Myeloma
Cancer/tumors
Lymphoproliferative Disorders
Treatment
ATAC-seq and ChIP-seq
Clinical Study ID
NCT05858203
RS1442/20
All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
- MM Patients
Exclusion
Exclusion Criteria:
- No exclusion criteria
Study Design
Total Participants: 150
Treatment Group(s): 1
Primary Treatment: ATAC-seq and ChIP-seq
Phase:
Study Start date:
December 22, 2020
Estimated Completion Date:
December 31, 2025
Connect with a study center
Regina elena Cancer Institute
Roma, 00144
ItalySite Not Available
"Regina Elena" National Cancer Institute
Rome, 00144
ItalyActive - Recruiting
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.